Denali Therapeutics Inc. – Filings and Transcripts

NASDAQ: DNLI
Share price (8/19/26): $25.69
Market cap (8/19/26): $4.106 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Automatic shelf registration

Ownership Filter

Schuth Alexander O.

Schuth Alexander O.

Baillie Gifford & Co

T. Rowe Price Investment Management, Inc.

News Filter

Reports Second Quarter 2026 Financial Results and Business Highlights

Completion of Acquisition or Disposition of Assets, Financial Statements or Exhibits

Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Shareholder Vote Results, Financial Statements or Exhibits

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Letter from the SEC